| Mr David Thomas Kwiatkowski, CRNA | |
|
6008 Ridgecarn Ave, Las Vegas, NV 89130-1373 | |
| (702) 644-2124 | |
| Not Available |
| Full Name | Mr David Thomas Kwiatkowski |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 27 Years |
| Location | 6008 Ridgecarn Ave, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083696900 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 2436 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alaska Native Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Native Tribal Health Consortium | 6709780265 | 457 |
News Archive
African-American and poor children in the United States suffer disproportionately from asthma. But according to a new study from sociologists at Rice University, racial and socio-economic gaps in the proportion of children in Houston who have asthma may be a result of social inequalities in the neighborhoods where children live.
A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.
Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.
GenVec, Inc. announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.
Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.
› Verified 6 days ago
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
African-American and poor children in the United States suffer disproportionately from asthma. But according to a new study from sociologists at Rice University, racial and socio-economic gaps in the proportion of children in Houston who have asthma may be a result of social inequalities in the neighborhoods where children live.
A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.
Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.
GenVec, Inc. announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.
Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr David Thomas Kwiatkowski, CRNA 6008 Ridgecarn Ave, Las Vegas, NV 89130-1373 Ph: (702) 644-2124 | Mr David Thomas Kwiatkowski, CRNA 6008 Ridgecarn Ave, Las Vegas, NV 89130-1373 Ph: (702) 644-2124 |
News Archive
African-American and poor children in the United States suffer disproportionately from asthma. But according to a new study from sociologists at Rice University, racial and socio-economic gaps in the proportion of children in Houston who have asthma may be a result of social inequalities in the neighborhoods where children live.
A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.
Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.
GenVec, Inc. announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.
Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.
› Verified 6 days ago
Morgan Che' Beeson, RN, MSN, CCRN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9127 W Russell Rd Ste 110, Las Vegas, NV 89148 Phone: 702-878-0070 Fax: 702-209-2064 | |
Gian Fule, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-383-2000 Fax: 702-209-2064 | |
Edgar Escobar, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-383-2000 | |
Johnette M Seecof, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2450 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-877-8661 | |
Kristi Vick, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 3186 S Maryland Pkwy, Las Vegas, NV 89109 Phone: 702-878-0070 | |
Mr. Vance Glenn Gainer Jr., CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4700 Las Vegas Blvd N, Las Vegas, NV 89191 Phone: 702-653-3526 |